Navigation Links
Mutation In PALB2 Elevates Risk of Cancer

Cancer is a complex and common disease caused by a combination of both genetic and environmental factors.

Recent research shows that the constitutional mutation in PALB2 gene elevates the risk of breast cancer four-fold. //

Previous studies have shown that genes are responsible for at least 5–10 per cent of all cases of breast cancer. The two major familial breast cancer susceptibility genes BRCA1 and BRCA2 only explain 20-30 per cent of families with site-specific female breast cancer, which suggests the contribution of additional susceptibility genes.

According to Dr Robert Winqvist, who coordinates the research effort, the identification of these genes may help to clarify the genetic background contributing to breast cancer and suggest novel pharmaceutical targets. It could also lead to genetic screening that identifies individuals at increased breast cancer risk and result in improved prevention efforts and treatment.

About a year ago, Dr Bing Xia and Professor David Livingston at the Dana-Farber Cancer Institute in Boston identified a novel BRCA2 binding factor, PALB2 that regulates certain key functions of normal BRCA2 activity. The next step was to set out to evaluate the newly detected PALB2 gene as a potential heritable breast cancer susceptibility candidate by screening for disease-related alterations. The results of this international research effort were recently published in Nature.

The research first involved comprehensive screening for genetic aberrations in 113 Finnish breast cancer families. The same constitutional mutation in PALB2 was observed in three families. It was later showed that the relevant mutant protein is deficient in its ability to support the kinds of DNA damage responses in which PALB2 normally participates. The mutation was further also investigated in 1,918 specimens from an unselected series of Finnish breast cancer individuals.

This study revealed 18 mutation-posi
'"/>




Page: 1 2

Related medicine news :

1. Mutation connected to Osteoporosis
2. Stem Cells Have Few Mutations
3. Gene Mutation Causes Ovarian Failure
4. Mutations in NOTCH1 cause an early developmental defect in the aortic valve
5. A Word Of Caution: Routine Screening For Breast Cancer Mutation Not Advisdable
6. Coffee Reduces Risk of Breast Cancer in BRCA1 Mutation Carriers
7. CCR5 Mutation Confers Immunity Against HIV But Not Against West Nile Virus Illness
8. Wound Healing Accelerated By Mutation In Deafness Gene
9. No Mutation Of Bird Flu Virus: WHO
10. Gene Mutation May Influence Age at Onset of Parkinsons Disease
11. Menin Gene Mutation made Insulin Secreting Cells to Proliferate
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Mutation PALB2 Elevates Risk Cancer

(Date:7/8/2008)...following statement was issued,today by the law fi...otice is hereby given that a class action lawsuit ...the Middle District of Tennessee on behalf,of all ...q: HWAY ),("Healthways" or the "Company") from Oc...e (the "Class Period")., If you wish to discuss t...
(Date:7/8/2008)...elays in Oxygen Orders, Lack of,Trained Technician... -- The new Medicare,competitive bidding program f...nd chaos for beneficiaries, physicians, hospital d...viders across the country since it,was implemented... program has triggered widespread disruptions in s...
(Date:7/8/2008)...ociety of Hematology (ASH) is proud to announce th... Pathway Grant. The grant is given to training pro...plementation of novel hematology-related training ...sity, Donald Mahoney Jr., MD, of Baylor College of...Sinai School of Medicine, will each receive the gr...
(Date:7/8/2008)...os Innovation,s Proprietary,Device-Free Remote Mo... and Medical Costs, N...ovations, a pioneer,in assisting clients to achiev...ce improvement through a device-free remote monito...e Iowa Medicaid Congestive Heart Failure,Populatio...
Breaking Medicine News(10 mins):Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 2Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 3Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 4Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 5Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 2Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 3
...test developed by a team led by a University of Le...rnment’s Independent Depleted Uranium// Oversight ...uranium (DU) during the 1991 Gulf Conflict. Ra...ology, developed the test with Postdoctoral Fellow...
...udying the genetic make-up using blood samples to ...g treatment, has been in practice//. Now, scientis...thods based on such existing tests that might reve...come victims of substance abuse or suffer antisoci...
...University of Iowa study has revealed that it may ...ions like panic disorder with blood tests//. This ...information in immature white blood cells. "The ...quantum leap in psychiatry," said the study's lead...
...searchers in the United States have developed a me...ll four types of the dengue// virus. The dengue v...cephalitis. The four types of virus are all suffic...iduals vaccinated against one virus type are still...
Other Medicine News:Health News:DU Test Finds UK Troops Uranium Free 2Health News:Genetic Tests to Reveal ‘substance Abuse’ Tendenci 2Health News:Genetic Tests to Reveal ‘substance Abuse’ Tendenci 3Health News:Mental Health Conditions Could Be Detected With Blood Tests 2
(Date:7/7/2008)...- Light Sciences Oncology, Inc.,(LSO) today announ...enign,prostatic hyperplasia (BPH), or enlargement ...(Litx(TM)), an innovative light-activated drug,tre...2-patient, Phase I/II,dose-escalation study at fou...nt, Phase IIa study in Australia, expected to begi...
(Date:7/7/2008)...irstCall/ -- Biopure Corporation,(Nasdaq: BPUR ) ...he Food,and Drug Administration (FDA) on identifyi...ical trial of Hemopure(R) [hemoglobin glutamer -,2... study use of Hemopure,in patients suffering from ...usion with blood components. Currently, AML patien...
(Date:7/6/2008)...horization Application currently ...- Cell Therapeutics, Inc. (...lication of results from its,randomized phase III ...,CT-2103) with gemcitabine or vinorelbine for the ...with previously untreated non-small cell,lung canc...
(Date:7/3/2008)...sachusetts, July 3,/-, -...ny, Jerini AG for an equity purchase price of EUR...oduct, FIRAZYR(R), to its Human Genetic Therapies ...es expected to be around $350-400 million, based ...ent, - Expected to be accretive for Non GAAP earn...
Breaking Medicine Technology:Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate 2Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate 3Biopure Announces Meeting With FDA 2Biopure Announces Meeting With FDA 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 2Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 3Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 4Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 5Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 6Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 7Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 8Drug Resistant Staph Infections Reaching Epidemic Levels in Some Parts of U S 4151 1Drug Resistant Staph Infections Reaching Epidemic Levels in Some Parts of U S 4151 2Drug Resistant Staph Infections Reaching Epidemic Levels in Some Parts of U S 4151 3Drug Resistant Staph Infections Reaching Epidemic Levels in Some Parts of U S 4151 4Nexia Closes Acquisition of Green Endeavors 3B Landis Salons On Track to Generate Revenues of 242 2 Million in 2007 4148 1Nexia Closes Acquisition of Green Endeavors 3B Landis Salons On Track to Generate Revenues of 242 2 Million in 2007 4148 2Nexia Closes Acquisition of Green Endeavors 3B Landis Salons On Track to Generate Revenues of 242 2 Million in 2007 4148 3Nexia Closes Acquisition of Green Endeavors 3B Landis Salons On Track to Generate Revenues of 242 2 Million in 2007 4148 4Syngenta Licenses Chromatin Gene Stacking Technology 1373 1Syngenta Licenses Chromatin Gene Stacking Technology 1373 2Research approved for Hawaiian military training area 888 1Research approved for Hawaiian military training area 888 2
...nt Plans - , ,OTTAWA, Canada – March 7, 2007...al company specializing in developing,advanced pro...ften,called “good cholesterol,” today ... of its lead product, CRD5. CRD5 is,being develope...ase. , ,Results showed, to date, that CRD5 was saf...
... 12, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB...ectious disease and dermatology, today announced t...emonstrated virtually no biofilm,formation in a 21...treated with Ceragenins,were soaked daily in a pho...atheter. At day 21, the catheters were challenged ...
Other Medicine Technology:Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 2Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 3Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: